AAX Biotech AB

AAX Biotech AB, based in Sweden, specializes in developing advanced antibody-based therapeutics to tackle significant drug development challenges. The company leverages proprietary technologies to enhance therapeutic outcomes for patients globally. AAX Biotech AB focuses on creating innovative antibody therapeutics. Founded in 2021 in Sweden, the company has completed one deal as of Feb 2026 The company's co-founders Mats AA Persson and Daniel X Johansson have a history in biotechnology.

AAX Biotech specializes in the development of advanced antibody-based therapeutics, leveraging proprietary technologies designed to address critical challenges in drug development. The company's core product offerings include Seqitope® and Opti-mAb®, which facilitate the generation of novel antibody therapeutics. Seqitope® provides insights into drug candidate interactions with targets, while Opti-mAb® enhances the efficacy and safety profiles of antibody medicines. These products target pharmaceutical companies in the biotherapeutics market, particularly in North America and Europe, addressing unmet medical needs across various disease areas to improve therapeutic outcomes for patients.

AAX Biotech's revenue model is primarily based on partnerships and collaborations with pharmaceutical companies that seek to develop and commercialize antibody-based therapies. These transactions usually involve licensing agreements, granting partners access to AAX Biotech’s proprietary technologies, Seqitope® and Opti-mAb®. The agreements may include milestone payments based on specific development and commercialization achievements, alongside royalties from sales of products developed using AAX’s technologies. AAX Biotech operates within the B2B sector, directing its specialized services at pharmaceutical firms rather than retail markets, emphasizing the value of its innovations in advancing therapeutics.

In February 2026, AAX Biotech AB raised an undisclosed amount of venture funding from new investor Trio Impact Invest. The company plans to utilize this funding to support its product development and expansion initiatives. AAX Biotech is looking to introduce new products aimed at enhancing therapeutic efficacy and safety. The company also targets expansion into additional markets, with specific regions in mind to grow its presence in the pharmaceutical biotherapeutics sector.